Literature DB >> 11160829

Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells.

R L Shoeman1, C Hüttermann, R Hartig, P Traub.   

Abstract

Electron microscopy of human skin fibroblasts syringe-loaded with human immunodeficiency virus type 1 protease (HIV-1 PR) revealed several effects on nuclear architecture. The most dramatic is a change from a spherical nuclear morphology to one with multiple lobes or deep invaginations. The nuclear matrix collapses or remains only as a peripheral rudiment, with individual elements thicker than in control cells. Chromatin organization and distribution is also perturbed. Attempts to identify a major nuclear protein whose cleavage by the protease might be responsible for these alterations were unsuccessful. Similar changes were observed in SW 13 T3 M [vimentin(+)] cells, whereas no changes were observed in SW 13 [vimentin(-)] cells after microinjection of protease. Treatment of SW 13 [vimentin(-)] cells, preinjected with vimentin to establish an intermediate filament network, with HIV-1 PR resulted in alterations in chromatin staining and distribution, but not in nuclear shape. These same changes were produced in SW 13 [vimentin(-)] cells after the injection of a mixture of vimentin peptides, produced by the cleavage of vimentin to completion by HIV-1 PR in vitro. Similar experiments with 16 purified peptides derived from wild-type or mutant vimentin proteins and five synthetic peptides demonstrated that exclusively N-terminal peptides were capable of altering chromatin distribution. Furthermore, two separate regions of the N-terminal head domain are primarily responsible for perturbing nuclear architecture. The ability of HIV-1 to affect nuclear organization via the liberation of vimentin peptides may play an important role in HIV-1-associated cytopathogenesis and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160829      PMCID: PMC30574          DOI: 10.1091/mbc.12.1.143

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  52 in total

1.  Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.

Authors:  K C Chou; A G Tomasselli; I M Reardon; R L Heinrikson
Journal:  Proteins       Date:  1996-01

2.  INMP, a novel intranuclear matrix protein related to the family of intermediate filament-like proteins: molecular cloning and sequence analysis.

Authors:  K Menz; N Radomski; E Jost
Journal:  Biochim Biophys Acta       Date:  1996-11-11

Review 3.  Extracellular matrix signaling from the cellular membrane skeleton to the nuclear skeleton: a model of gene regulation.

Authors:  S Lelièvre; V M Weaver; M J Bissell
Journal:  Recent Prog Horm Res       Date:  1996

4.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

5.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

6.  Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication.

Authors:  A Bergamini; L Dini; M Capozzi; L Ghibelli; R Placido; E Faggioli; A Salanitro; E Buonanno; L Cappannoli; L Ventura; M Cepparulo; L Falasca; G Rocchi
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

7.  Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle.

Authors:  E K Thomas; R J Connelly; S Pennathur; L Dubrovsky; O K Haffar; M I Bukrinsky
Journal:  Viral Immunol       Date:  1996       Impact factor: 2.257

8.  Intermediate filament protein domain interactions as revealed by two-hybrid screens.

Authors:  J J Meng; S Khan; W Ip
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

9.  Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.

Authors:  J R Rosé; L M Babé; C S Craik
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Risk factors for non-Hodgkin's lymphomas in acquired immunodeficiency syndrome (AIDS)

Authors:  H K Armenian; D R Hoover; S Rubb; S Metz; O Martinez-Maza; J Chmiel; L Kingsley; A Saah
Journal:  Am J Epidemiol       Date:  1996-02-15       Impact factor: 4.897

View more
  14 in total

1.  Onset of human cytomegalovirus replication in fibroblasts requires the presence of an intact vimentin cytoskeleton.

Authors:  Matthew S Miller; Laura Hertel
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

2.  Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.

Authors:  Nathan W Cummins; Amy M Sainski-Nguyen; Sekar Natesampillai; Fatma Aboulnasr; Scott Kaufmann; Andrew D Badley
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

3.  Heroin-Induces Differential Protein Expression by Normal Human Astrocytes (NHA).

Authors:  Jessica L Reynolds; Supriya D Mahajan; Donald Sykes; Madhavan P N Nair
Journal:  Am J Infect Dis       Date:  2006

4.  Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikunar Aalinkeel; Bindukumar Nair; Donald E Sykes; Anardi Agosto-Mujica; Chiu Bin Hsiao; Stanley A Schwartz
Journal:  J Clin Immunol       Date:  2009-06-20       Impact factor: 8.317

5.  Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.

Authors:  Hailiu Yang; Joseph Nkeze; Richard Y Zhao
Journal:  Cell Biosci       Date:  2012-09-12       Impact factor: 7.133

6.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

7.  Nucleocytoplasmic shuttling of cytoskeletal proteins: molecular mechanism and biological significance.

Authors:  Masahiro Kumeta; Shige H Yoshimura; James Hejna; Kunio Takeyasu
Journal:  Int J Cell Biol       Date:  2011-12-20

8.  Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin.

Authors:  Anna Litwiniec; Lidia Gackowska; Anna Helmin-Basa; Agnieszka Zuryń; Alina Grzanka
Journal:  Cancer Cell Int       Date:  2013-02-05       Impact factor: 5.722

Review 9.  Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.

Authors:  Zukile Mbita; Rodney Hull; Zodwa Dlamini
Journal:  Viruses       Date:  2014-08-19       Impact factor: 5.048

10.  Identification of Vimentin as a Potential Therapeutic Target against HIV Infection.

Authors:  Celia Fernández-Ortega; Anna Ramírez; Dionne Casillas; Taimi Paneque; Raimundo Ubieta; Marta Dubed; Leonor Navea; Lila Castellanos-Serra; Carlos Duarte; Viviana Falcon; Osvaldo Reyes; Hilda Garay; Eladio Silva; Enrique Noa; Yassel Ramos; Vladimir Besada; Lázaro Betancourt
Journal:  Viruses       Date:  2016-06-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.